セファピリンナトリウム

危険有害性情報のコード(GHS)

• 絵表示(GHS)

  

• 注意喚起語

  Danger

• 危険有害性情報

  H315：皮膚刺激

  H317：アレルギー性皮膚反応を起こすおそれ

  H319：強い眼刺激

  H334：吸入するとアレルギー、喘息または、呼吸困難 を起こすおそれ

  H335：呼吸器への刺激のおそれ

• 注意書き

  P261：粉じん/煙/ガス/ミスト/蒸気/スプレーの吸入を避ける こと。

  P280：保護手袋/保護衣/保護眼鏡/保護面を着用するこ と。

  P284：呼吸用保護具を着用すること。

  P304+P340：吸入した場合：空気の新鮮な場所に移し、呼吸しやすい 姿勢で休息させること。

  P305+P351+P338：眼に入った場合：水で数分間注意深く洗うこと。次にコ ンタクトレンズを着用していて容易に外せる場合は外す こと。その後も洗浄を続けること。

  P342+P311：呼吸に関する症状が出た場合：医師に連絡すること。

セファピリンナトリウム 価格

セファピリンナトリウム 化学特性,用途語,生産方法

• 外観

  白色〜うすい黄色, 結晶〜粉末

• 溶解性

  水に溶け、エタノール及びアセトンにほとんど溶けない。

• 効能

  抗生物質, 細胞壁合成阻害薬

• 使用上の注意

  アルゴン封入

• 説明

  Cephapirin sodium (Cefapirin sodium), a semisynthetic cephalosporin antibiotic, is bactericidal against strains of gram-positive and gram-negative bacteria.
  Cephapirin is closely resembles cephalothin in chemical and pharmacokinetic properties. Cephapirin, have cephalosporanic acid core with the acetyloxymethyl group at the 3rd position and having IUPAC name (6R,7R)-3-(Acetoxymethy)-8- oxo-7-{[(pyridin-4-ylsulfanyl)acetyl]amino}-5-thia- 1-azabicyclo [4.2.0] oct-2-ene-2-carboxylic acid. It is unstable in acid and must be administered parenteral. It has similar mechanism as other cephalosporins. It is marketed under the trade name Cefadyl. It is effective against a wide variety of gram-positive and gramnegative bacteria; used as the sodium salt. Among the most serious adverse reactions of cefapirin, that is， neutropenia, leukopenia, anemia, bone marrowdepression, and allergic reactions, it has been discontinued in the United States (Wiesner, 1972).

• 化学的特性

  White or pale yellow powder.

• 定義

  ChEBI: Cephapirin sodium is the sodium salt of cephapirin. A first-generation cephalosporin antibiotic, it is effective against gram-negative and gram-positive organisms. Being more resistant to beta-lactamases than penicillins, it is effective agains most staphylococci, though not methicillin-resistant staphylococci. It has a role as an antibacterial drug. It is a cephalosporin and an organic sodium salt. It contains a cephapirin(1-).

• 主な応用

  Cephapirin was synthesized by BristolMyers Laboratories in 1970. It shows almost the same in vitro antibacterial activity as cephalothin, but its in vivo effects are slightly greater than those of cephalothin. Like cephalothin, it is metabolized in vivo, and its deacetylated metabolite shows almost the same activity against gram-positive bacteria as cephalothin, but weaker activity against gramnegative bacteria. Cephapirin has been used for therapy of urinary tract infections and osteomyelitis caused by Staphylococcus, Streptococcus, and Escherichia coli.

セファピリンナトリウム 上流と下流の製品情報

セファピリンナトリウム 生産企業

Global(179)Suppliers

24356-60-3, セファピリンナトリウム キーワード